
About AIM Biotech
AIM Biotech is a Healthcare company based in Singapore (Singapore) founded in 2012. Microfluidic 3D cell culture systems are developed and manufactured. AIM Biotech offers products and services including organiX, idenTx, AngioPrime, and VasQ Kit. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Cell Biology. Its legal entity is AIM Biotech Pte. Ltd.
Company details
A spinout from MIT, AIM Biotech develops and manufactures microfluidic devices for research applications, beginning with 3D cell culture systems. AIMs 3D cell culture chips enable multicellular models to be established in extracellular matrices of the users choice (e.g. collagen, Matrigel, etc.). Stable gradients of pressure or chemicals can be established to model interstitial flow or concentration gradients respectively. Applications developed to date include cell migration, angiogenesis, cancer metastasis (intra-extravasation, spheroid dispersion), chemotaxis and stem cell differentiation. These models can also be used for screening compounds that affect these biological processes. AIM chips are consumables designed to be used with standard cell biology lab equipment without the need for new capital expenditures. AIM Biotech will supply chips accessories to the research community initially, and will expand into the provision of testing services for the pharmaceutical industry. Some key features of AIM microfluidic chips are - Long working regions that are easily injectable with hydrogel, with low risk of leakage; Gas permeable bottom laminate ensures accurate reflections of incubator conditions (normoxic or hypoxic); Multicellular co-culture, with meaningful organization into models of biological systems; Control over chemical gradients and flow across the gel region andor within the media channels. AIM claims its chips provide easy to cast hydrogels for 3D cell culture, and provide excellent optical clarity for various imaging techniques.
- Headquarters Singapore, Singapore
- SectorsHealthcare
- Website aimbiotech.com
- Social LinkedIn X Facebook
- Legal Name Aim Biotech Pte. Ltd.
- Annual Revenue$4.25 K (USD)as on Dec 31, 2015
- Net Profit-$120.27 K (USD)as on Dec 31, 2015
- InvestorsWavemaker Partners
& 4 more
Products & Services of AIM Biotech
AIM Biotech offers a comprehensive portfolio of products and services, including organiX, idenTx, AngioPrime, and VasQ Kit.
Enables culture of human tissues for drug discovery research.
Facilitates scalable organ-on-a-chip experiments for testing.
Supports human-relevant models for predictive drug analysis.
Provides tools for vascular biology and drug efficacy studies.
Funding Insights of AIM Biotech
- Total Rounds 1
- Investors Count 5
All 1 funding rounds of AIM Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2021 | Series A | β | Wavemaker Partners |
5 investors in total: 5 institutional.
Investors in AIM Biotech
AIM Biotech has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Wavemaker Partners, SEEDS Capital and Wavemaker 360.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in early-stage technology companies are made by Wavemaker Partners. | 2003 | wavemaker.vc | Los Angeles, United States | |
Government-backed fund investing in tech startups | seedscapital.sg | Singapore, Singapore | ||
| wavemaker360.com | ||||
Venture capital is provided to early-stage technology startups. | elev8.vc | Singapore, Singapore | ||
Investor details for AIM Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AIM Biotech
1 people are tracked at AIM Biotech (1 in leadership).
| Name | Role | Group |
|---|---|---|
Chee Mun Kuan | Executive Director & Co-Founder | Leadership |
Complete people profiles for AIM Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AIM Biotech
2 dated milestones of AIM Biotech across 9 years, from founding to its latest funding, stage changes and deals.
- Founded AIM Biotech is founded.
- Funding First funding round.
Web traffic of AIM Biotech
The website of AIM Biotech (aimbiotech.com) receives about 2.7K visits a month.
- Monthly visits2.7K
▲ 24.4% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aim Biotech
Complete news archive for AIM Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AIM Biotech
AIM Biotech was founded in 2012 and raised its 1st funding round 9 years after it was founded.
AIM Biotech is headquartered in Singapore, Singapore.
Annual revenue of AIM Biotech is $4.25K as on Dec 31, 2015.
A spinout from MIT, AIM Biotech develops and manufactures microfluidic devices for research applications, beginning with 3D cell culture systems. AIMs 3D cell culture chips enable multicellular models to be established in extracellular matrices of the users choice (e.g. collagen, Matrigel, etc.). Stable gradients of pressure or chemicals can be established to model interstitial flow or concentration gradients respectively. Applications developed to date include cell migration, angiogenesis, cancer metastasis (intra-extravasation, spheroid dispersion), chemotaxis and stem cell differentiation. These models can also be used for screening compounds that affect these biological processes. AIM chips are consumables designed to be used with standard cell biology lab equipment without the need for new capital expenditures. AIM Biotech will supply chips accessories to the research community initially, and will expand into the provision of testing services for the pharmaceutical industry. Some key features of AIM microfluidic chips are - Long working regions that are easily injectable with hydrogel, with low risk of leakage; Gas permeable bottom laminate ensures accurate reflections of incubator conditions (normoxic or hypoxic); Multicellular co-culture, with meaningful organization into models of biological systems; Control over chemical gradients and flow across the gel region andor within the media channels. AIM claims its chips provide easy to cast hydrogels for 3D cell culture, and provide excellent optical clarity for various imaging techniques.
AIM Biotech offers organiX, idenTx, AngioPrime, and VasQ Kit.
AIM Biotech has 5 investors. Key investors include Wavemaker Partners, SEEDS Capital, Wavemaker 360, Black Kite Investments, and Elev8.vc.
AIM Biotech operates through Aim Biotech Pte. Ltd..
